301 related articles for article (PubMed ID: 32462248)
1. [Checkpoint inhibitors in Hodgkin lymphoma].
Sasse S; Momotow J; Engert A
Internist (Berl); 2020 Jul; 61(7):660-668. PubMed ID: 32462248
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
Bröckelmann PJ; Goergen H; Keller U; Meissner J; Ordemann R; Halbsguth TV; Sasse S; Sökler M; Kerkhoff A; Mathas S; Hüttmann A; Bormann M; Zimmermann A; Mettler J; Fuchs M; von Tresckow B; Baues C; Rosenwald A; Klapper W; Kobe C; Borchmann P; Engert A
JAMA Oncol; 2020 Jun; 6(6):872-880. PubMed ID: 32352505
[TBL] [Abstract][Full Text] [Related]
3. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
5. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
[TBL] [Abstract][Full Text] [Related]
6. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.
Reinke S; Bröckelmann PJ; Iaccarino I; Garcia-Marquez M; Borchmann S; Jochims F; Kotrova M; Pal K; Brüggemann M; Hartmann E; Sasse S; Kobe C; Mathas S; Soekler M; Keller U; Bormann M; Zimmermann A; Richter J; Fuchs M; von Tresckow B; Borchmann P; Schlößer H; von Bergwelt-Baildon M; Rosenwald A; Engert A; Klapper W
Blood; 2020 Dec; 136(25):2851-2863. PubMed ID: 33113552
[TBL] [Abstract][Full Text] [Related]
7. [Not Available].
Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
[TBL] [Abstract][Full Text] [Related]
8. Back to life with checkpoint inhibitors in Hodgkin lymphoma.
Dada R; Zekri J
J Oncol Pharm Pract; 2018 Mar; 24(2):139-142. PubMed ID: 28597713
[TBL] [Abstract][Full Text] [Related]
9. Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab.
De Filippi R; Morabito F; Santoro A; Tripepi G; D'Alò F; Rigacci L; Ricci F; Morelli E; Zinzani PL; Pinto A
J Transl Med; 2021 Dec; 19(1):489. PubMed ID: 34852840
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.
Ramchandren R; Domingo-Domènech E; Rueda A; Trněný M; Feldman TA; Lee HJ; Provencio M; Sillaber C; Cohen JB; Savage KJ; Willenbacher W; Ligon AH; Ouyang J; Redd R; Rodig SJ; Shipp MA; Sacchi M; Sumbul A; Armand P; Ansell SM
J Clin Oncol; 2019 Aug; 37(23):1997-2007. PubMed ID: 31112476
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
[TBL] [Abstract][Full Text] [Related]
12. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
[TBL] [Abstract][Full Text] [Related]
13. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
14. Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.
Hradska K; Kascak M; Hajek R; Jelinek T
Expert Rev Hematol; 2020 Apr; 13(4):375-392. PubMed ID: 32116068
[No Abstract] [Full Text] [Related]
15. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P; Engert A; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman JM; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Shipp MA; Kato K; Sumbul A; Farsaci B; Ansell SM
J Clin Oncol; 2018 May; 36(14):1428-1439. PubMed ID: 29584546
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: a meta-analysis of prospective clinical study.
Amraee A; Evazi MR; Shakeri M; Roozbeh N; Ghazanfarpour M; Ghorbani M; Ansari J; Darvish L
Clin Transl Oncol; 2019 Aug; 21(8):1093-1103. PubMed ID: 30739242
[TBL] [Abstract][Full Text] [Related]
17. Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas.
Dilly-Feldis M; Aladjidi N; Refait JK; Parrens M; Ducassou S; Rullier A
Pediatr Blood Cancer; 2019 May; 66(5):e27571. PubMed ID: 30637917
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.
Pianko MJ; Moskowitz AJ; Lesokhin AM
Clin Cancer Res; 2018 Mar; 24(5):1002-1010. PubMed ID: 28899972
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint Inhibition in Hodgkin Lymphoma - a Review.
Bröckelmann PJ; Engert A
Oncol Res Treat; 2017; 40(11):654-660. PubMed ID: 29065424
[TBL] [Abstract][Full Text] [Related]
20. Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors.
Vardhana S; Cicero K; Velez MJ; Moskowitz CH
Oncologist; 2019 Jan; 24(1):86-95. PubMed ID: 30082490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
